國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Myelodysplastic syndromesdiagnosis -...

Fenaux, Pierre.

Myelodysplastic syndromesdiagnosis - prognosis - therapy /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Myelodysplastic syndromesedited by Uwe Platzbecker, Pierre Fenaux.
其他題名:	diagnosis - prognosis - therapy /
其他作者:	Platzbecker, Uwe.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	v, 157 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Myelodysplastic syndromesDiagnosis.
電子資源:	http://dx.doi.org/10.1007/978-3-319-76879-3
ISBN:	9783319768793$q(electronic bk.)

Myelodysplastic syndromesdiagnosis - prognosis - therapy /
Myelodysplastic syndromesdiagnosis - prognosis - therapy /[electronic resource] :edited by Uwe Platzbecker, Pierre Fenaux. - Cham :Springer International Publishing :2018. - v, 157 p. :ill., digital ;24 cm. - Hematologic malignancies,2197-9766. - Hematologic malignancies..

Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation.

This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.

ISBN: 9783319768793$q(electronic bk.)

Standard No.: 10.1007/978-3-319-76879-3doiSubjects--Topical Terms:

819287
Myelodysplastic syndromes
--Diagnosis.

LC Class. No.: RC645.73 / .M945 2018

Dewey Class. No.: 616.41

Myelodysplastic syndromesdiagnosis - prognosis - therapy /
LDR:02589nmm a2200325 a 4500 001 540809
003 DE-He213
005 20190111102510.0
006 m d
007 cr nn 008maaau
008 190308s2018 gw s 0 eng d
020 $a 9783319768793$q(electronic bk.)
020 $a 9783319768786$q(paper)
024 7 $a 10.1007/978-3-319-76879-3 $2 doi
035 $a 978-3-319-76879-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC645.73 $b .M945 2018
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
082 0 4 $a 616.41 $2 23
090 $a RC645.73 $b .M996 2018
245 0 0 $a Myelodysplastic syndromes $h [electronic resource] : $b diagnosis - prognosis - therapy / $c edited by Uwe Platzbecker, Pierre Fenaux.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a v, 157 p. : $b ill., digital ; $c 24 cm.
490 1 $a Hematologic malignancies, $x 2197-9766
505 0 $a Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation.
520 $a This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
650 0 $a Myelodysplastic syndromes $x Diagnosis. $3 819287
650 0 $a Myelodysplastic syndromes $x Treatment. $3 819288
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Hematology. $3 274899
650 2 4 $a Oncology. $3 195181
700 1 $a Platzbecker, Uwe. $3 819285
700 1 $a Fenaux, Pierre. $3 819286
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Hematologic malignancies. $3 560151
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-76879-3
950 $a Medicine (Springer-11650)